Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (XTRA:LLY) from Neutral to Buy. As of April 2, 2025, the average one-year price target for Eli Lilly and is ...

Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (SNSE:LLY) from Neutral to Buy. There are 5,513 funds or institutions reporting positions in Eli Lilly and.

Eli Lilly and Company (NYSE:LLY) is included among the 11 Defensive Healthcare Dividend Stocks to Buy Now. Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical company. The ...